Prenatal screening for trisomy II trimester of pregnancy (biochemical screening II trimester of pregnancy, the "triple test» II trimester) — a set of research being undertaken to pregnant women in order to assess the risk of fetal anomalies — Down syndrome (trisomy of chromosome 21), Edwards syndrome (trisomy 18) neural tube defects (NTDs).
What indicators are included in the "triple test» II trimester?
- Human chorionic gonadotropin (hCG, beta-hCG);
- Alpha-fetoprotein (AFP);
- Free estriol
What are the indications for "triple test"?
Prenatal screening for trisomy II trimesters of pregnancy is carried to all pregnant women. Specific indications include:
- women over the age of 35 years;
- the presence of a child (or a history — of the fetus aborted pregnancy) with genetically confirmed Down syndrome and other chromosomal diseases, congenital malformations;
- hereditary disease in the immediate family;
- radiation exposure or other harmful effects on one's spouse before conception.
At what stage of pregnancy is carried II trimester prenatal screening?
Optimal timing of the survey — from 16 to 18 weeks of pregnancy.
What should be the preparation for the "triple test» I trimester?
For this study, you must have the results of fetal ultrasound made no earlier than one week prior to analysis.
What are the dates of performance analysis?
How are the results of the "triple test» I trimester?
The results of calculating the risk of chromosomal abnormalities are not the basis for a diagnosis, and are an indication for further special methods of investigation on the advice of the obstetrician-gynecologist.